Read our insights and commentary about pharmaceutical industry news and healthcare innovation globally. Subscribe to our monthly newsletter to keep up to date with our thought leadership, news, and updates.
Showing 5 of 134 posts
May 12, 2019 | Research posters
ISPOR International 2019: The Importance of Overall Survival as a Clinical Endpoint in FDA vs. EMA Regulatory Approval
ISPOR International 2019: CBPartners presented a poster about the importance of overall survival (OS) data as a clinical endpoint in FDA vs. EMA regulatory approval.
May 9, 2019 | Videos
US Market Access Trends: CBPartners' Andrew Gould asks a panel of US payers what they see the role of ICER being today, and becoming in the future.
May 3, 2019 | Videos
US Market Access Trends: CBPartners' Andrew Gould asks a panel of US payers which market access challenges are currently keeping them up at night.
May 1, 2019 | Blogs
PART II of CBPartners' CNS series:
April 25, 2019 | Blogs
While advanced therapies such as cell and gene therapy have disrupted the healthcare industry, there is much that is still unknown – as well the current appetite for such therapies will wane as their approvals become more common, and the budget implications become real. CBPartners' Cell and Gene Therapy Center of Excellence explores the short and long-term commercial outlook for cell and gene therapies.